The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) is a cohesive and extensive group of Neuro-Ophthalmologists, other doctors, coordinators, biostatisticians, clinical trial experts and reading centers, who have developed a structured organization to perform prospective clinical research with the support of the National Eye Institute of the NIH, other funding agencies, and industry.
The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) is a cohesive extensive group of Neuro-Ophthalmologists and other doctors, who have developed a structured organization to perform prospective clinical research with the support of the National Eye Institute of the NIH, other funding agencies, and industry. Neuro-Ophthalmology is a subspecialty of Neurology and Ophthalmology that addresses scientific and medical aspects that bridge both specialties. There is a broad spectrum of Neuro-Ophthalmologic disorders that collectively affect millions of people. Many of these are visual disorders associated with other systemic or neurological conditions. Almost all of these fit the US Government definition as “rare” diseases. While some affect larger numbers of people (e.g., optic neuritis in multiple sclerosis), most affect fewer individuals (e.g. idiopathic intracranial hypertension, nonarteritic anterior ischemic optic neuropathy, thyroid eye disease) and have infrequently been the subject of prospective research. Thus, there is often little consensus among practitioners on the diagnostic evaluation or therapy for many Neuro-Ophthalmological disorders.
NORDIC was created, to provide the organization and operational capability to address these and other crucial unanswered questions and pursue new clinical trial research over a broad range of scientific and medical issues that affect vision, eye movements, pupil function and visual quality of life. NORDIC performs multi-site observational and treatment trials that concern disease risk, diagnosis, treatment and other management-aspects of those disease entities or new therapies, which could not be studied without a clinical research organization.
More information can be obtained from the head of NORDIC, Dr. Mark Kupersmith. Please use the NANOS Member Directory to get his contact information (member login required).
NANOS IN THE NEWS